Search or
𝛼SK
𝛼SKSun Pharmaceutical (SUNP IN): Checkpoint Acquisition Does Not Check All the Boxes
476 Views10 Mar 2025 09:47
SUMMARY
- Sun Pharmaceutical Industries (SUNP IN) (SPIL) announced the plan to acquire Checkpoint Therapeutics (CKPT US), a commercial stage immunotherapy and targeted oncology company, for ~$200M.
- In December, Checkpoint has received FDA approval for its maiden drug, Unloxcyt (cosibelimab), for the treatment of certain type of skin cancer. Unloxcyt has peak sales estimate of $1.6B.
- SPIL’s offer for Checkpoint seems compelling and provides superior risk-adjusted value. However, the acquisition will not be near-term value generator for SPIL, which doesn’t have good track record for acquisition.
Related Insights
More »- Sun Pharmaceutical Industries: Halol Observations Were Critical, No Relief to Plant.
- Sun Pharmaceutical (SUNP IN): Timely Succession Plan to Augur Well for Next-Level of Growth
- How Acquiring Checkpoint Therapeutics Inc Adds Value to Sun Pharma?
- Sun Pharmaceutical Industries: Checkpoint Acquisition to Strengthen Specialty Business.
- Sun Pharmaceutical Industries: Checkpoint Acquisition to Strengthen Specialty Business
Trending Collections
More »Trending Insights
More »- UK: Slowdown Softened In Q2
- S&P/ASX Index Rebalance Preview (Sep 25): Potential Changes if Methodology Is Updated
- Value Unlock SG: Value Creation Via Corporate Action. May the Wind Carry Many More Sails
- Quiddity Leaderboard CSI 300/500 Dec25: Trade Moving in the Right Direction; Large Flows Expected
- Kangji Medical (9997 HK): Q&A With The FA
Top Unpaywalled Insights
More »- [IO Technicals 2025/33] China Woes Deepen, Bearish Momentum Grips Iron Ore
- Tradesmen's Collective: Fixing the Trades with Tech, Transparency & Boots-on-the-Ground
- VEON 2Q25: Solid Digital Non-Telco Products Uplift, Kyivstar Listing in Focus
- [IO Technicals 2025/32] Bullish Momentum Builds
- Grab Holdings (GRAB US) - Harvesting Sequentially
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Sun Pharmaceutical (SUNP IN): Timely Succession Plan to Augur Well for Next-Level of Growth14 Jun 2025
- Sun Pharmaceutical (SUNP IN): Checkpoint Acquisition Does Not Check All the Boxes10 Mar 2025
x